Peptides for Erectile Dysfunction & Sexual Performance

Erectile dysfunction (ED) affects an estimated 4.3 million men in the UK, with prevalence increasing significantly after age 40. While PDE5 inhibitors like sildenafil (Viagra) remain the frontline treatment, a growing body of research examines peptide-based approaches that work through entirely different mechanisms — particularly melanocortin receptor agonists and hypothalamic neuropeptides.

Unlike conventional ED medications that act on blood vessel smooth muscle, peptides such as PT-141 (bremelanotide) target the central nervous system to modulate sexual arousal at the brain level. This distinction is clinically important for the significant subset of men whose ED has a psychological or neurological component rather than purely vascular.

The peptide research landscape for sexual health also includes kisspeptin, which stimulates the hypothalamic-pituitary-gonadal axis, and oxytocin, which influences arousal and bonding pathways. Each operates through fundamentally different mechanisms, offering potential options for men who don't respond to conventional treatments.

All information presented is for educational purposes based on published research. ED is a medical condition that warrants proper assessment by a GP or urologist, as it can be an early indicator of cardiovascular disease.